(Q38101601)

28 August 2017

title

Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia (English)

1 reference

28 August 2017

0 references

1 reference

Jacqueline Barrientos

series ordinal

1

object named as

Jacqueline Barrientos

1 reference

28 August 2017

Kanti Rai

2

1 reference

28 August 2017

language of work or name

1 reference

1 August 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

54

1 reference

28 August 2017

issue

8

1 reference

28 August 2017

page(s)

1817-1820

1 reference

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.796049

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.796049

Chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.796049

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.796049

Bruton tyrosine kinase (BTK) and its role in B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.796049

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.796049

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.796049

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.796049

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.796049

10.3109/10428194.2013.796049

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference